MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on December 6, 2005; DOI: 10.1124/mol.105.019174


0026-895X/06/6903-991-997$20.00
Mol Pharmacol 69:991-997, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.019174v1
69/3/991    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hejazi, N.
Right arrow Articles by Zhang, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hejazi, N.
Right arrow Articles by Zhang, L.

{Delta}9-Tetrahydrocannabinol and Endogenous Cannabinoid Anandamide Directly Potentiate the Function of Glycine Receptors

Nadia Hejazi, Chunyi Zhou, Murat Oz, Hui Sun, Jiang Hong Ye, and Li Zhang

Laboratory of Integrative Neuroscience, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, Maryland (N.H., H.S., L.Z.); Departments of Anesthesiology (C.Z., J.H.Y.) and Pharmacology and Physiology (J.H.Y.); University of Medicine and Dentistry of New Jersey Medical School, Newark, New Jersey (C.Z., J.H.Y); and Cellular Neurobiology Branch, National Institute on Drug Abuse, National Institutes of Health, Washington, DC (M.O.)

Anandamide (AEA) and {Delta}9-tetrahydrocannabinol (THC) are endogenous and exogenous ligands, respectively, for cannabinoid receptors. Whereas most of the pharmacological actions of cannabinoids are mediated by CB1 receptors, there is also evidence that these compounds can produce effects that are not mediated by the activation of identified cannabinoid receptors. Here, we report that THC and AEA, in a CB1 receptor-independent manner, cause a significant potentiation of the amplitudes of glycine-activated currents (IGly) in acutely isolated neurons from rat ventral tegmental area (VTA) and in Xenopus laevis oocytes expressing human homomeric ({alpha}1) and heteromeric ({alpha}1beta1) subunits of glycine receptors (GlyRs). The potentiation of IGly by THC and AEA is concentration-dependent, with respective EC50 values of 86 ± 9 and 319 ± 31 nM for {alpha}1 homomeric receptors, 73 ± 8 and 318 ± 24 nM for {alpha}1beta1 heteromeric receptors, and 115 ± 13 and 230 ± 29 nM for native GlyRs in VTA neurons. The effects of THC and AEA are selective for IGly, because GABA-activated current in VTA neurons or in X. laevis oocytes expressing {alpha}2beta3{gamma}2 GABAA receptor subunits were unaffected by these compounds. The maximal potentiation by THC and AEA was observed at the lowest concentration of glycine; with increasing concentrations of glycine, the potentiation significantly decreased. The site for THC and AEA seems to be distinct from that of the alcohol and volatile anesthetics. The results indicate that THC and AEA, in pharmacologically relevant concentrations, directly potentiate the function of GlyRs through an allosteric mechanism.


Received September 22, 2005; accepted November 8, 2005

Address correspondence to: Dr. Li Zhang, Laboratory for Integrative Neuroscience National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 5625 Fishers Lane, Bethesda, MD 20892. E-mail: lzhang{at}mail.nih.gov




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
W. Xiong, M. Hosoi, B.-N. Koo, and L. Zhang
Anandamide Inhibition of 5-HT3A Receptors Varies with Receptor Density and Desensitization
Mol. Pharmacol., February 1, 2008; 73(2): 314 - 322.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Oz, K.-H. Yang, M. Dinc, and T. S. Shippenberg
The Endogenous Cannabinoid Anandamide Inhibits Cromakalim-Activated K+ Currents in Follicle-Enclosed Xenopus Oocytes
J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 547 - 554.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. E. Spivak, C. R. Lupica, and M. Oz
The Endocannabinoid Anandamide Inhibits the Function of {alpha}4beta2 Nicotinic Acetylcholine Receptors
Mol. Pharmacol., October 1, 2007; 72(4): 1024 - 1032.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
A. Fisyunov, V. Tsintsadze, R. Min, N. Burnashev, and N. Lozovaya
Cannabinoids Modulate the P-Type High-Voltage-Activated Calcium Currents in Purkinje Neurons
J Neurophysiol, September 1, 2006; 96(3): 1267 - 1277.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics